Observational Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2020; 26(25): 3673-3685
Published online Jul 7, 2020. doi: 10.3748/wjg.v26.i25.3673
Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area
Lin Yuan, Jun-Bo Zhao, Ying-Lei Zhou, Ya-Bin Qi, Qiong-Ya Guo, Hai-Hui Zhang, Muhammad Noman Khan, Ling Lan, Chang-He Jia, Yan-Rui Zhang, Song-Ze Ding
Lin Yuan, Jun-Bo Zhao, Ying-Lei Zhou, Ya-Bin Qi, Qiong-Ya Guo, Hai-Hui Zhang, Muhammad Noman Khan, Ling Lan, Chang-He Jia, Yan-Rui Zhang, Song-Ze Ding, Department of Gastroenterology and Hepatology, People's Hospital of Zhengzhou University, Henan Province, China
Lin Yuan, Jun-Bo Zhao, Ying-Lei Zhou, Ya-Bin Qi, Qiong-Ya Guo, Hai-Hui Zhang, Muhammad Noman Khan, Ling Lan, Chang-He Jia, Yan-Rui Zhang, Song-Ze Ding, Henan Provincial People’s Hospital, Henan Province, China
Ying-Lei Zhou, Ya-Bin Qi, Qiong-Ya Guo, Hai-Hui Zhang, Muhammad Noman Khan, Ling Lan, Chang-He Jia, Yan-Rui Zhang, Song-Ze Ding, Henan University School of Medicine, Zhengzhou 450003, Henan Province, China
Author contributions: Yuan L, Lan L, Zhang YR and Ding SZ designed the research; Yuan L, Zhao JB, Zhou YL, Qi YB, Guo QY, Zhang HY, Khan MN and Jia CH collected clinical data and performed experiments; Yuan L analyzed the data; Yuan L and Ding SZ wrote the paper; Ding SZ revised the article; All authors have approved the final version of the manuscript.
Supported by National Natural Science Foundation of China, No. U1604174; Henan Provincial Government-Health and Family Planning Commission, No. 20170123; Henan Provincial Government-Health and Family Planning Commission Research Innovative Talents Project, No. 51282; and Henan Provincial Government-Science and Technology Bureau, No. 142300410050.
Institutional review board statement: This study was approved by the Ethics Committee of People’s Hospital of Zhengzhou University (ID: 2019-KY-No. 10), Zhengzhou, China.
Conflict-of-interest statement: Authors declare no competing interests.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Song-Ze Ding, MD, PhD, Chief Doctor, Professor, Department of Gastroenterology and Hepatology, People’s Hospital of Zhengzhou University, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, Henan Province, China. dingsongze@hotmail.com
Received: January 4, 2020
Peer-review started: February 24, 2020
First decision: March 27, 2020
Revised: April 8, 2020
Accepted: June 4, 2020
Article in press: June 4, 2020
Published online: July 7, 2020
Processing time: 185 Days and 11.6 Hours
Core Tip

Core tip: Type I and type II Helicobacter pylori (H. pylori) infection status and their impact on gastrin-17 and pepsinogen level in chronic gastric diseases have not been studied in this high gastric cancer risk area. Our results show that type I H. pylori infection is the major form of infection, and a very low percentage (11.6%) of gastric cancer patients are not infected by H. pylori. Both type I and type II H. pylori induce an increase in gastrin-17 level, while type I H. pylori is the major strain that affects pepsinogen (PG) I, PG II level and PG I/PG II ratio in stepwise gastric disease in this geographic area.